Form 4: Aquestive CDO Granted 50,000 Shares, Options

Aquestive Therapeutics' Chief Development Officer, Matthew W. Davis, was granted 50,000 shares of restricted stock and 50,000 non-qualified stock options.

Summary

• Matthew W. Davis, Chief Development Officer of Aquestive Therapeutics, Inc. (AQST), acquired 50,000 shares of common stock and 50,000 non-qualified stock options on November 10, 2025.
• The common stock is restricted stock, which will vest in three annual installments: 25% on the first installment, 25% on the second installment, and 50% on the third installment.
• The non-qualified stock options have an exercise price of $5.58 per share and will also vest in three annual installments: 25% on the first installment, 25% on the second installment, and 50% on the third installment.
• Both the restricted stock and options were acquired at a price of $0, indicating they are grants as part of compensation.
• The options have an expiration date of November 10, 2035.

Sentiment

Score: 7

Explanation: The grant of equity to a key executive is generally a positive signal as it aligns management's interests with shareholders. It's a standard compensation practice and doesn't indicate immediate operational or financial issues, but rather a long-term incentive.

Positives

• The grant of restricted stock and stock options aligns the Chief Development Officer's financial interests with those of shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice to attract and retain key executives in the biotechnology industry.

Negatives

• The vesting schedule means the executive does not immediately fully own the granted equity, tying a significant portion of compensation to continued employment and future performance.
• The options' value is dependent on the future stock price exceeding the exercise price of $5.58.

Risks

• The value of the granted equity is subject to the volatility of Aquestive Therapeutics' stock price.
• If the executive's employment terminates before the vesting schedule is complete, unvested shares and options may be forfeited.
• Future dilution for existing shareholders could occur upon the exercise of options and vesting of restricted stock.

Future Outlook

The equity grants, with their multi-year vesting schedule, indicate a long-term commitment from the Chief Development Officer to Aquestive Therapeutics' future performance and strategic objectives. The company anticipates continued contributions from this key executive.

Industry Context

Equity grants, including restricted stock and stock options, are a common and essential component of executive compensation packages in the biotechnology and pharmaceutical industries. They are used to attract, retain, and motivate top talent by linking their personal wealth to the company's long-term success and shareholder value creation. This grant is consistent with typical compensation practices for a Chief Development Officer in a publicly traded biotech firm.

Comparison to Industry Standards

• The structure of this equity grant, combining restricted stock and stock options with a multi-year vesting schedule, is a standard compensation practice widely observed across the biotechnology and pharmaceutical sectors.
• Companies like Moderna, BioNTech, and Pfizer frequently utilize similar equity-based incentives for their senior executives to align interests with long-term strategic goals and R&D milestones.
• The exercise price of $5.58 for the options is set at the market price on the grant date, which is typical for non-qualified stock options, ensuring the executive benefits only if the stock price appreciates from that point.

Related Party Transactions

• This filing details an executive compensation grant to Matthew W. Davis, the Chief Development Officer, which is a transaction between the company and a key management personnel.

Stakeholder Impact

• Shareholders: The grant aims to align the Chief Development Officer's interests with shareholder value creation. However, the future vesting and exercise of these equity instruments could lead to minor dilution.
• Employees: This grant reflects the company's compensation strategy for senior leadership, potentially influencing broader compensation philosophies within the organization.
• Management: The Chief Development Officer receives a significant equity incentive, tying a substantial portion of their future compensation to the company's stock performance and long-term success.

Next Steps

• The restricted stock and non-qualified stock options will vest in three annual installments, with 25% on the first, 25% on the second, and 50% on the third installment, starting from the grant date of November 10, 2025.

Key Dates

Keywords

Aquestive Therapeutics, AQST, Form 4, stock grant, stock options, restricted stock, executive compensation, insider transaction, Chief Development Officer